AI-Powered Research

Patients with acute myocardial infarction:
- 50 years or older
- acute myocardial infarction (AMI) within 10 days prior to baseline measurements
- clinically stable and able to undergo a PET/CT scan;Patients with ischemic stroke:
- 50 years or older
- Ischemic stroke within 10 days prior to baseline measurements
- Clinically stable and able to undergo a PET/CT scan;Matched controls:
- 50 years or older
- clinically no evident (CV) disease and able to undergo a PET/CT scan

Exclusion Criteria

- Known systemic disorder such as hepatic, renal, hematologic, and malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator
- Participation in a scientific study with radiation exposure in the year prior to inclusion
- Planned radiation exposure in the next year due to participation in a research project with radiation exposure
- Recent (< 1 month prior to screening) or current treatment with medications that may have a significant effect on the inflammatory state, including: oral, rectal, or injectable corticosteroids or immunosuppressive medications
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are difference in 18F-DPA-714 or signal on PET/CT in<br /><br>culprit (infarcted region of the heart or cerebrum) and non-culprit lesions<br /><br>(non-infarcted regions of the heart or cerebrum, peripheral atherosclerotic<br /><br>lesions), as well in the spleen and bone marrow between patients with an acute<br /><br>cardiovascular event versus matched controls. Furthermore, the change in<br /><br>18F-DPA-714 on PET/CT within the group with an acute cardiovascular event<br /><br>between the acute phase and after 3 months will be determined. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secundary study parameters are difference in monocyte and circulating<br /><br>progenitor cell subtypes and extracellular markers between the AMI and stable<br /><br>patients and the change monocyte and circulating progenitor cell subtypes and<br /><br>extracellular markers within the AMI patients in the acute phase, after 3<br /><br>months and after six months. Furthermore, the difference between the pet signal<br /><br>of the tracers DPA-714 will be measured. </p><br>